

Curriculum Vitae Europass

Informazioni personali

Nome: Dr. Josuel Ora
Data di nascita: 15/04/1978, Roma (Italia)
Indirizzo: 00152 Roma, Italia
Telefono: +39 *****
Email: josuel.ora@ptvonline.it
PEC: josuel.ora@omceoromapec.it
Codice Fiscale: ROAJSL78D15H501R



Esperienza lavorativa

Dal 30/12/2009 – in corso: Dirigente Medico di I livello presso la Fondazione PTV – Policlinico Tor Vergata, Viale Oxford 81, Roma (00133)

- Attività svolta presso l'U.O.C. di Malattie dell'Apparato Respiratorio sotto la direzione dei Prof. Cesare Saltini, Prof. Mario Cazzola e attualmente Prof.ssa Paola Rogliani.
- Attività clinica prevalentemente in ambulatorio (asma grave, BPCO, pneumologia generale) e nel laboratorio di fisiopatologia respiratoria e test da sforzo cardiopolmonare.
- Attività di guardia del reparto pneumologico, servizio di broncoscopia e consulenze per PS, OBI, reparti di Medicina e Chirurgia.
- Competenze specifiche: ventilazione meccanica non invasiva, ossigenoterapia, ecografia toracica, toracentesi, emergenze cardiorespiratorie, interpretazione e applicazioni cliniche dell'emogasanalisi.

Dal 13/09/2019 – in corso: Responsabile Qualità U.O.C. di Malattie dell'Apparato Respiratorio.

Dal 01/07/2022 – in corso: Incarico professionalizzante di alta specialità Fondazione PTV – Policlinico Tor Vergata, Roma dal titolo dell'incarico: "Gestione ambulatoriale integrata delle patologie ostruttive".

Esperienza didattica

2020 - ad oggi: Università Tor Vergata, Roma – Coordinatore Didattico Master I livello in Tecniche di Fisiopatologia Respiratoria, Docente di Malattie Polmonari (corso in italiano e inglese).

2024 - ad oggi: Università Unicamillus, Roma – Docente di Respiratory System Diseases (corso di laurea in Medicina e Chirurgia, lingua inglese).

2015 - 2024: Università Cattolica 'Nostra Signora del Buon Consiglio', Tirana (Albania) – Professore a contratto di Malattie Respiratorie.

2015 - ad oggi: Università Tor Vergata, Roma – Tutor e docente alla Scuola di Specializzazione in Malattie del Sistema Respiratorio.

2009 - ad oggi: Relatore a congressi nazionali e internazionali (AIPO, ERS, ecc.).

Istruzione e formazione

2003 – Laurea in Medicina e Chirurgia, Università di Roma La Sapienza, 110/110 e lode.

2008 – Specializzazione in Medicina Interna, Università di Roma La Sapienza, 70/70 e lode.

2007-2009 – Post-Doctoral Fellow, Queen's University, Kingston, Canada.

2019 – Master II livello in Management Sanitario, Università Niccolò Cusano, Roma.

2024 – Dottorato di Ricerca in Medicina Sperimentale e dei Sistemi, Università Tor Vergata.

Abilitazioni Scientifiche Nazionali: Professore Associato (2021), Professore Ordinario (2023).

Iscritto all'Ordine dei Medici Chirurghi e Odontoiatri di Roma, n. 52902 (dal 2003).

Competenze personali

Lingua madre: Italiano

Altre lingue: Inglese (C1 – Certificate of Advanced English, Cambridge ESOL)

Competenze comunicative: consolidate grazie all'attività di docente e relatore in congressi.

Competenze organizzative: coordinamento di Master universitari e gruppi di ricerca.

Competenze professionali: pneumologia clinica, fisiopatologia respiratoria, riabilitazione respiratoria, ricerca clinica.

Competenze digitali: uso avanzato di banche dati scientifiche, software statistici e strumenti di didattica digitale.

Attività di ricerca

Aree di ricerca: test da sforzo cardiopolmonare, meccanica respiratoria, dispnea, asma, BPCO, broncodilatatori, meta-analisi, strategie terapeutiche innovative.

Collaborazioni con gruppi di ricerca nazionali e internazionali.

Autore di oltre 100 articoli scientifici indicizzati su Scopus (H-index: 28, citazioni >2900).

Affiliazioni

European Respiratory Society (ERS) – dal 2009

Associazione Italiana di Pneumologia Ospedaliera (AIPO) – dal 2015

Consiglio Esecutivo Regionale Lazio AIPO – dal 2015

Coordinatore macroarea Fisiopatologia Respiratoria AIPO – dal 2018

pubblicazioni

Elenco di tutte le pubblicazioni e documenti disponibili su scopus (eccetto il primo che non è ancora disponibile su scopus in quanto appena pubblicato, ma rintracciabile tramite il DOI)

1. Sepiacchi A, Starc N, Laitano R, Pasqua F, Rogliani P, **Ora J**. Systematic Review and Meta-Analysis of the Application of T-PEP in the Therapeutic Management of COPD Patients. *Journal of Clinical Medicine* [Internet]. 2025;14(2). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85216081884&doi=10.3390%2fjcm14020320&partnerID=40&md5=50f2d5339c24d6faea73fb60c993102f>
2. De Benedittis G, Latini A, Morgante C, Bonini C, Cela E, Kroegler B, et al. Alteration of telomere length and mtDNA copy number in interstitial lung disease associated with rheumatoid arthritis. *Autoimmunity* [Internet]. 2025;58(1). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-86000444844&doi=10.1080%2f08916934.2025.2473741&partnerID=40&md5=d2b401c904fcdb426111e9ac3745a77a>
3. Phillips DB, James MD, Vincent SG, Elbehairy AF, Neder JA, Kirby M, et al. Physiological Characterization of Preserved Ratio Impaired Spirometry in the CanCOLD Study Implications for Exertional Dyspnea and Exercise Intolerance. *American Journal of Respiratory and Critical Care Medicine* [Internet]. 2024;209(11):1314–27. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85194916717&doi=10.1164%2fajrccm.202307-1184OC&partnerID=40&md5=f054f899a9d58f421fbc70e371df497f>
4. **Ora J**, Rogliani P. Clinical challenges in applying the new lung function test interpretive strategies: navigating pitfalls and possible solutions. *European Respiratory Journal* [Internet]. 2024;63(1). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85183589827&doi=10.1183%2f13993003.01439-2023&partnerID=40&md5=fd19a76d415d1f082c969ceb854d4b27>
5. **Ora J**, Giorgino FM, Bettin FR, Gabriele M, Rogliani P. Pulmonary Function Tests: Easy Interpretation in Three Steps. *Journal of Clinical Medicine* [Internet]. 2024;13(13). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85198486954&doi=10.3390%2fjcm13133655&partnerID=40&md5=9a510d03a470d3d0069ff11e631c8d23>
6. **Ora J**, De Marco P, Motta E, Laitano R, Calzetta L, Rogliani P. Real-World Efficacy of Biological Therapies in Severe Asthma: A Focus on Small Airways. *Journal of Clinical Medicine* [Internet]. 2024;13(19). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85206583867&doi=10.3390%2fjcm13195883&partnerID=40&md5=79cf296d4d97ac6dca06a3641a1f124f>
7. **Ora J**, De Marco P, Gabriele M, Cazzola M, Rogliani P. Exercise-Induced Asthma: Managing Respiratory Issues in Athletes. *Journal of Functional Morphology and Kinesiology* [Internet]. 2024;9(1). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85188902623&doi=10.3390%2fjfmk9010015&partnerID=40&md5=fc1a522ef29dbe9a07fce7529cd3118b>
8. Matera MG, **Ora J**, Calzetta L, Rogliani P, Cazzola M. Biologics for asthma and risk of pneumonia. *Journal of Asthma* [Internet]. 2024;61(9):905–11. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85184456901&doi=10.1080%2f02770903.2024.2311236&partnerID=40&md5=d1121c9e1027db8638acc1d2031f4344>
9. Cazzola M, **Ora J**, Maniscalco M, Rogliani P. A clinician's guide to single vs multiple inhaler therapy for COPD. *Expert Review of Respiratory Medicine* [Internet]. 2024;18(7):457–

68. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85200051810&doi=10.1080%2f17476348.2024.2384702&partnerID=40&md5=6a7ac958e0177e0b56e0c1fee8f1e897>
10. Cazzola M, **Ora J**, Calzetta L, Rogliani P, Matera MG. β -Blockers and Asthma: Surprising findings from the FAERS database. *Respiratory Medicine* [Internet]. 2024;234. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85207793008&doi=10.1016%2fj.rmed.2024.107849&partnerID=40&md5=7c3d8952a501265ce47a96755ae33a99>
11. Salton F, Confalonieri P, Centanni S, Mondoni M, Petrosillo N, Bonfanti P, et al. Prolonged higher dose methylprednisolone versus conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS). *European Respiratory Journal* [Internet]. 2023;61(4). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85148936444&doi=10.1183%2f13993003.01514-2022&partnerID=40&md5=f1ed057dd4dff95b09370b64cb01de61>
12. Rogliani P, Radovanovic D, **Ora J**, Starc N, Verri S, Pistocchini E, et al. Assessing the relationship between cardiovascular and small airway disease and acute events in COPD: The ARCADIA study protocol. *Pulmonary Pharmacology and Therapeutics* [Internet]. 2023;82. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85165699199&doi=10.1016%2fj.pupt.2023.102231&partnerID=40&md5=b8c329383ab6146050de8aef9febc10d>
13. Rogliani P, Laitano R, **Ora J**, Beasley R, Calzetta L. Strength of association between comorbidities and asthma: a meta-analysis. *European Respiratory Review* [Internet]. 2023;32(167). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85149643647&doi=10.1183%2f16000617.0202-2022&partnerID=40&md5=7a310fa700f29ac2f0912d6e59975900>
14. **Ora J**, Rogliani P, Ferron F, Vignuoli M, Valentino L, Pontoni G, et al. Effects of SARS-CoV-2 on Pulmonary Function and Muscle Strength Testing in Military Subjects According to the Period of Infection: Cross-Sectional Study. *Diagnostics* [Internet]. 2023;13(10). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85160524810&doi=10.3390%2fdiagnostics13101679&partnerID=40&md5=9988a6e01e098360e90c6a9bd89596de>
15. **Ora J**, Calzetta L, Frugoni C, Puxeddu E, Rogliani P. Expert guidance on the management and challenges of long-COVID syndrome: a systematic review. *Expert Opinion on Pharmacotherapy* [Internet]. 2023;24(3):315–30. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85145474199&doi=10.1080%2f14656566.2022.2161365&partnerID=40&md5=14e8cafde62fa2fa605c8822487fb34b>
16. Matera MG, Rogliani P, **Ora J**, Calzetta L, Cazzola M. A comprehensive overview of investigational elastase inhibitors for the treatment of acute respiratory distress syndrome. *Expert Opinion on Investigational Drugs* [Internet]. 2023;32(9):793–802. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85172158146&doi=10.1080%2f13543784.2023.2263366&partnerID=40&md5=588c24c39c311c03a48fa3da8caf92ba>
17. Matera MG, **Ora J**, Rogliani P, Cazzola M. An overview of the preclinical discovery and development of tezepelumab for the treatment of asthma. *Expert Opinion on Drug Discovery* [Internet]. 2023;18(9):951–63. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85164187610&doi=10.1080%2f17460441.2023.2230885&partnerID=40&md5=ec2bcbe7fbc548ca33dd2a39f4667003>
18. Matera MG, **Ora J**, Calzetta L, Rogliani P, Cazzola M. Investigational anti IL-13 asthma treatments: a 2023 update. *Expert Opinion on Investigational Drugs* [Internet]. 2023;32(5):373–

86. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85159683701&doi=10.1080%2f13543784.2023.2215425&partnerID=40&md5=d2c2b445a4d1a04485ff7c7496ebbe84>
19. Matera MG, Calzetta L, Cazzola M, **Ora J**, Rogliani P. Biologic therapies for chronic obstructive pulmonary disease. Expert Opinion on Biological Therapy [Internet]. 2023;23(2):163–73. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85145289365&doi=10.1080%2f14712598.2022.2160238&partnerID=40&md5=e2c5df68ccf314458d68e10f3fae62e1>
20. Manzetti GM, **Ora J**, Sepiacchi A, Cazzola M, Rogliani P, Calzetta L. Clinically Important Deterioration (CID) and Ageing in COPD: A Systematic Review and Meta-Regression Analysis According to PRISMA Statement. International Journal of COPD [Internet]. 2023;18:2225–43. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85174464931&doi=10.2147%2fCOPD.S396945&partnerID=40&md5=17587069297661f235ec5afd5283960c>
21. Cazzola M, Rogliani P, **Ora J**, Calzetta L, Lauro D, Matera MG. Hyperglycaemia and Chronic Obstructive Pulmonary Disease. Diagnostics [Internet]. 2023;13(21). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85176389020&doi=10.3390%2fdiagnostics13213362&partnerID=40&md5=63f103e0b250067719b15b4e814f8c14>
22. Cazzola M, Rogliani P, **Ora J**, Calzetta L, Matera MG. Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences. Therapeutic Advances in Chronic Disease [Internet]. 2023;14. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85161300481&doi=10.1177%2f20406223231171556&partnerID=40&md5=94ba27c49de5b5ce6b5152aef6809589>
23. Calzetta L, Chetta A, Aiello M, Frizzelli A, **Ora J**, Melis E, et al. The BNT162b2 mRNA COVID-19 Vaccine Increases the Contractile Sensitivity to Histamine and Parasympathetic Activation in a Human Ex Vivo Model of Severe Eosinophilic Asthma. Vaccines [Internet]. 2023;11(2). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85149208019&doi=10.3390%2fvaccines11020282&partnerID=40&md5=18a782d3275388fcd664147e8aec2529>
24. Rogliani P, Ritondo BL, Cavalli F, Giorgino FM, Girolami A, Pane G, et al. Synergy across the drugs approved for the treatment of asthma. Minerva Medica [Internet]. 2022;113(1):17–30. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85128330405&doi=10.23736%2fS0026-4806.21.07266-9&partnerID=40&md5=13e5ccffa2b5cddb4f6c97067d5210c>
25. Rogliani P, **Ora J**, Cavalli F, Cazzola M, Calzetta L. Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and Ibis Score. Journal of Clinical Medicine [Internet]. 2022;11(15). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85136917141&doi=10.3390%2fjcm11154491&partnerID=40&md5=655a58c84ba6703bee3871116dc108dd>
26. Rogliani P, **Ora J**, Calzetta L, Matera MG, Cazzola M. Asthma and comorbidities: recent advances. Polish Archives of Internal Medicine [Internet]. 2022;132(4). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85129643232&doi=10.20452%2fpamw.16250&partnerID=40&md5=bf2d5f0a766b4258ec0266976f2617df>
27. **Ora J**, Zerillo B, De Marco P, Manzetti GM, De Guido I, Calzetta L, et al. Effects of SARS-CoV-2 Infection on Pulmonary Function Tests and Exercise Tolerance. Journal of Clinical Medicine [Internet]. 2022;11(17). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0->

85137766848&doi=10.3390%2fjcm11174936&partnerID=40&md5=f8fcb1d80d2b40e4b9c06c3fa2defe92

28. **Ora J**, Prendi E, Ritondo BL, Pata X, Spada F, Rogliani P. Pulmonary Rehabilitation in Noncystic Fibrosis Bronchiectasis. *Respiration* [Internet]. 2022;101(1):97–105. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85112381358&doi=10.1159%2f000517527&partnerID=40&md5=7e426c7081c59055070d73e8a2738bb6>

29. **Ora J**, Prendi E, Attinà ML, Cazzola M, Calzetta L, Rogliani P. Efficacy of respiratory tele-rehabilitation in COPD patients: Systematic review and meta-analysis. *Monaldi Archives for Chest Disease* [Internet]. 2022;92(4). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85137091998&doi=10.4081%2fmonaldi.2022.2105&partnerID=40&md5=3b08ca815f0859e4f41e42725d5a504a>

30. **Ora J**, Coppola A, Perduno A, Manzetti GM, Puxeddu E, Rogliani P. Acute effect of oxygen therapy on exercise tolerance and dyspnea perception in ILD patients. *Monaldi Archives for Chest Disease* [Internet]. 2022;92(2). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85129779537&doi=10.4081%2fmonaldi.2021.1925&partnerID=40&md5=c72e3084693506019069d94e4856e1f0>

31. Cazzola M, Rogliani P, Calzetta L, **Ora J**, Matera MG. A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD. *Expert Review of Clinical Pharmacology* [Internet]. 2022;15(3):269–83. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85130272041&doi=10.1080%2f17512433.2022.2071700&partnerID=40&md5=65c182d074a994682e4cdd0f5538ae4a>

32. Cazzola M, **Ora J**, Calzetta L, Rogliani P, Matera MG. The future of inhalation therapy in chronic obstructive pulmonary disease. *Current Research in Pharmacology and Drug Discovery* [Internet]. 2022;3. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85124739798&doi=10.1016%2fj.crphar.2022.100092&partnerID=40&md5=f5d15fef10f2fe6ea2f29936f7fb87e3>

33. Cazzola M, **Ora J**, Calzetta L, Rogliani P, Matera MG. Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today? *Expert Opinion on Pharmacotherapy* [Internet]. 2022;23(8):917–27. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85130921919&doi=10.1080%2f14656566.2022.2076592&partnerID=40&md5=8136fe2b8966f9465ac654eab4ee48fc>

34. Rogliani P, **Ora J**, Girolami A, Rossi I, de Guido I, Facciolo F, et al. Ceiling effect of beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in COPD: A translational bench-to-bedside study. *Pulmonary Pharmacology and Therapeutics* [Internet]. 2021;69. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85109105394&doi=10.1016%2fj.pupt.2021.102050&partnerID=40&md5=889c170f99487984c68d338a4d51bd5e>

35. **Ora J**, Rogliani P, Dauri M, O'Donnell D. Happy hypoxemia, or blunted ventilation? *Respiratory Research* [Internet]. 2021;22(1). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85098800159&doi=10.1186%2fs12931-020-01604-9&partnerID=40&md5=ae5de1406d7350ba40457f35fb5024e3>

36. **Ora J**, Calzetta L, Ritondo BL, Matera MG, Rogliani P. Current long-acting muscarinic antagonists for the treatment of asthma. *Expert Opinion on Pharmacotherapy* [Internet]. 2021;22(17):2343–57. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0->

85110930953&doi=10.1080%2f14656566.2021.1952182&partnerID=40&md5=68fb7d06d4360844cd3401d043dda82d

37. Matera MG, **Ora J**, Cavalli F, Rogliani P, Cazzola M. New avenues for phosphodiesterase inhibitors in asthma. *Journal of Experimental Pharmacology* [Internet]. 2021;13:291–302. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103285360&doi=10.2147%2fJEP.S242961&partnerID=40&md5=6067f209ef8f912280cce893f0926bcf>

38. Matera MG, **Ora J**, Calzetta L, Rogliani P, Cazzola M. Sex differences in COPD management. *Expert Review of Clinical Pharmacology* [Internet]. 2021;14(3):323–32. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102566770&doi=10.1080%2f17512433.2021.1888713&partnerID=40&md5=7c7e2e0b4678247dc52dd28eeb77b366>

39. Matera MG, Calzetta L, **Ora J**, Rogliani P, Cazzola M. Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs. *Expert Opinion on Drug Delivery* [Internet]. 2021;18(7):891–906. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099648656&doi=10.1080%2f17425247.2021.1873271&partnerID=40&md5=0f7a3f0b337af2c86e69418950d5d50f>

40. Liguori C, Pierantozzi M, Spanetta M, Sarmati L, Cesta N, Iannetta M, et al. Depressive and anxiety symptoms in patients with SARS-CoV2 infection. *Journal of Affective Disorders* [Internet]. 2021;278:339–40. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091570041&doi=10.1016%2fj.jad.2020.09.042&partnerID=40&md5=05cfl42435ab5bc545ea50e5e69f76>

41. Cazzola M, Rogliani P, Salvi SS, **Ora J**, Matera MG. Use of Thiols in the Treatment of COVID-19: Current Evidence. *Lung* [Internet]. 2021;199(4):335–43. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85113689457&doi=10.1007%2fs00408-021-00465-3&partnerID=40&md5=e68a3ca8c2f13545f6a75ec946fd067b>

42. Cazzola M, **Ora J**, Cavalli F, Rogliani P, Matera MG. Treatable Mechanisms in Asthma. *Molecular Diagnosis and Therapy* [Internet]. 2021;25(2):111–21. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100812273&doi=10.1007%2fs40291-021-00514-w&partnerID=40&md5=8169cf520e42ac353e270bc1f5997bb3>

43. Cazzola M, **Ora J**, Cavalli F, Rogliani P, Matera MG. An overview of the safety and efficacy of monoclonal antibodies for the chronic obstructive pulmonary disease. *Biologics: Targets and Therapy* [Internet]. 2021;15:363–74. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85114174421&doi=10.2147%2fBTT.S295409&partnerID=40&md5=ba1ae1297155b201ed6106bc12dde4d1>

44. Cazzola M, **Ora J**, Bianco A, Rogliani P, Matera MG. Management of COPD patients during COVID: difficulties and experiences. *Expert Review of Respiratory Medicine* [Internet]. 2021;15(8):1025–33. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106243600&doi=10.1080%2f17476348.2021.1929176&partnerID=40&md5=d4634287d83e0c6bbfab02ff1181dcfd>

45. Cazzola M, **Ora J**, Bianco A, Rogliani P, Matera MG. Guidance on nebulization during the current COVID-19 pandemic. *Respiratory Medicine* [Internet]. 2021;176. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85098471988&doi=10.1016%2fj.rmed.2020.106236&partnerID=40&md5=9bdd7ecbb1a6b811a8e6f9957f99b187>

46. Cazzola M, Matera MG, Rogliani P, Calzetta L, **Ora J**. Step-up and step-down approaches in the treatment of asthma. *Expert Review of Respiratory Medicine* [Internet]. 2021;15(9):1159–68. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0->

85107463830&doi=10.1080%2f17476348.2021.1935245&partnerID=40&md5=1de92dcb208b285e581aec0888a60236

47. Rogliani P, Ritondo BL, **Ora J**, Cazzola M, Calzetta L. SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. *European Respiratory Journal* [Internet]. 2020;56(3). Available from: [https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089602797&doi=10.1183%2f13993003.00625-](https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089602797&doi=10.1183%2f13993003.00625-2020&partnerID=40&md5=e29f6c5cc1e03b8ba35ca0c86845bef8)

2020&partnerID=40&md5=e29f6c5cc1e03b8ba35ca0c86845bef8

48. Paone G, De Rose G, **Ora J**. Basic key aspects of physiology of idiopathic pulmonary fibrosis. In: *Respiratory Ventilatory Strategies in Acute and Chronic Respiratory Failure in Idiopathic Pulmonary Diseases: A Practical Approach* [Internet]. 2020. p. 17–25. Available from: [https://www.scopus.com/inward/record.uri?eid=2-s2.0-](https://www.scopus.com/inward/record.uri?eid=2-s2.0-85144562159&partnerID=40&md5=d037c0b935bc117eda8ec4c31d07fa82)

85144562159&partnerID=40&md5=d037c0b935bc117eda8ec4c31d07fa82

49. **Ora J**, Puxeddu E, Cavalli F, Giorgino FM, Girolami A, Chioocchi M, et al. Does bronchoscopy help the diagnosis in COVID-19 infection? *European Respiratory Journal* [Internet]. 2020;56(2). Available from: [https://www.scopus.com/inward/record.uri?eid=2-s2.0-](https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089302124&doi=10.1183%2f13993003.01619-2020&partnerID=40&md5=7cb67bfa4279f023d2ed98deb9fe0faa)

85089302124&doi=10.1183%2f13993003.01619-2020&partnerID=40&md5=7cb67bfa4279f023d2ed98deb9fe0faa

50. **Ora J**, Liguori C, Puxeddu E, Coppola A, Matino M, Pierantozzi M, et al. Dyspnea perception and neurological symptoms in non-severe COVID-19 patients. *Neurological Sciences* [Internet]. 2020;41(10):2671–4. Available from:

[https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088818432&doi=10.1007%2fs10072-](https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088818432&doi=10.1007%2fs10072-020-04632-x&partnerID=40&md5=8558b755d9c26569a26ad2b67b438d0a)

51. **Ora J**, Coppola A, Cazzola M, Calzetta L, Rogliani P. Long-acting muscarinic antagonists under investigational to treat chronic obstructive pulmonary disease. *Journal of Experimental Pharmacology* [Internet]. 2020;12:559–74. Available from:

[https://www.scopus.com/inward/record.uri?eid=2-s2.0-](https://www.scopus.com/inward/record.uri?eid=2-s2.0-85098112865&doi=10.2147%2fJEP.S259330&partnerID=40&md5=28dd5a15ecc7ea347456ce571af0aade)

52. **Ora J**, Cavalli F, Cazzola M. Management of patients with asthma or COPD and cardiovascular disease: Risks versus benefits. *ERS Monograph* [Internet].

2020;2020(9781849841191):66–81. Available from:

[https://www.scopus.com/inward/record.uri?eid=2-s2.0-](https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089710460&doi=10.1183%2f2312508X.10027419&partnerID=40&md5=321d6611e9a8542d78ca97ffb6b17e32)

53. **Ora J**, Calzetta L, Matera MG, Cazzola M, Rogliani P. Advances with glucocorticoids in the treatment of asthma: state of the art. *Expert Opinion on Pharmacotherapy* [Internet].

2020;21(18):2305–16. Available from: [https://www.scopus.com/inward/record.uri?eid=2-s2.0-](https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089558076&doi=10.1080%2f14656566.2020.1807514&partnerID=40&md5=f4a941f56ccb8dbac0c666394146d29f)

85089558076&doi=10.1080%2f14656566.2020.1807514&partnerID=40&md5=f4a941f56ccb8dbac0c666394146d29f

54. Liguori C, Pierantozzi M, Spanetta M, Sarmati L, Cesta N, Iannetta M, et al. Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. *Brain, Behavior, and Immunity* [Internet]. 2020;88:11–6. Available from:

[https://www.scopus.com/inward/record.uri?eid=2-s2.0-](https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085771174&doi=10.1016%2fj.bbi.2020.05.037&partnerID=40&md5=38bc23127ef0892d2222540a2b1e9b2d)

55. Rogliani P, Calzetta L, **Ora J**, Cazzola M, Matera MG. Efficacy and safety profile of doxofylline compared to theophylline in asthma: A meta-analysis. *Multidisciplinary Respiratory Medicine* [Internet]. 2019;14(1). Available from:

[https://www.scopus.com/inward/record.uri?eid=2-s2.0-85070218455&doi=10.1186%2fs40248-](https://www.scopus.com/inward/record.uri?eid=2-s2.0-85070218455&doi=10.1186%2fs40248-019-0189-0&partnerID=40&md5=fdbd4641f34f2310a8c474853a0bc03c)

56. Rogliani P, Calzetta L, Matera MG, di Daniele N, Girolami A, Cazzola M, et al. Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. *Expert Opinion on Pharmacotherapy* [Internet]. 2019;20(6):737–50. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063431177&doi=10.1080%2f14656566.2019.1570133&partnerID=40&md5=9f57176d9451065b531d5bc81a62409d>
57. Cazzola M, Puxeddu E, **Ora J**, Rogliani P. Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers. *Molecular Diagnosis and Therapy* [Internet]. 2019;23(5):603–14. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069935670&doi=10.1007%2fs40291-019-00413-1&partnerID=40&md5=876ac90edbcda1c0f54ab82d87a4ea74>
58. Rogliani P, **Ora J**, Puxeddu E, Calzetta L, Cavalli F, Matera MG, et al. Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. *Pulmonary Pharmacology and Therapeutics* [Internet]. 2018;49:20–6. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042795988&doi=10.1016%2fj.pupt.2017.12.010&partnerID=40&md5=dabb5068af8738da1f2569fe300c1bf8>
59. Rogliani P, **Ora J**, Matera MG, Cazzola M, Calzetta L. The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. *Expert Opinion on Drug Safety* [Internet]. 2018;17(6):589–96. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048307129&doi=10.1080%2f14740338.2018.1472232&partnerID=40&md5=c5dac55c78e9ef95f8b3bb5f059b8a84>
60. Rogliani P, **Ora J**, Di Daniele N, Lauro D. Pleiotropic effects of hypoglycemic agents: implications in asthma and COPD. *Current Opinion in Pharmacology* [Internet]. 2018;40:34–8. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041425270&doi=10.1016%2fj.coph.2018.01.002&partnerID=40&md5=df58e9fcefa75ab39b97717f8c152aa8>
61. Matera MG, Rogliani P, **Ora J**, Cazzola M. Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. *Expert Opinion on Pharmacotherapy* [Internet]. 2018;19(18):2043–53. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058565438&doi=10.1080%2f14656566.2018.1534957&partnerID=40&md5=24b1f03c26b0af886cdf0b3b475d726f>
62. Faverio P, De Giacomi F, Sardella L, Fiorentino G, Carone M, Salerno F, et al. Management of acute respiratory failure in interstitial lung diseases: Overview and clinical insights. *BMC Pulmonary Medicine* [Internet]. 2018;18(1). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85047068745&doi=10.1186%2fs12890-018-0643-3&partnerID=40&md5=59c88d20b8abd559dc69cd9f4f8bd0d7>
63. Cazzola M, Rogliani P, Puxeddu E, **Ora J**, Matera MG. An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? *Expert Review of Respiratory Medicine* [Internet]. 2018;12(1):43–54. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85038232673&doi=10.1080%2f17476348.2018.1398086&partnerID=40&md5=a501258ce3fa96c87121c90048341897>
64. Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, et al. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: An international case-cohort study. *European Respiratory Journal* [Internet]. 2017;50(2). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85023612291&doi=10.1183%2f13993003.00936-2017&partnerID=40&md5=68d646aa8e6cc212c3387071f1c94732>

65. Rogliani P, **Ora J**, Puxeddu E, Matera MG, Cazzola M. Adherence to COPD treatment: Myth and reality. *Respiratory Medicine* [Internet]. 2017;129:117–23. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85021091111&doi=10.1016%2fj.rmed.2017.06.007&partnerID=40&md5=0b6da4e52b1711e97fe25e4463282786>
66. Rogliani P, Matera MG, **Ora J**, Cazzola M, Calzetta L. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: A quantitative synthesis. *International Journal of COPD* [Internet]. 2017;12:3469–85. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85037732675&doi=10.2147%2fCOPD.S146338&partnerID=40&md5=0b780b942517f53eee95218478e7e665>
67. Rogliani P, Calzetta L, Coppola A, Cavalli F, **Ora J**, Puxeddu E, et al. Optimizing drug delivery in COPD: The role of inhaler devices. *Respiratory Medicine* [Internet]. 2017;124:6–14. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85010280751&doi=10.1016%2fj.rmed.2017.01.006&partnerID=40&md5=0cade940eff45b281f69b58b0e229424>
68. Cazzola M, **Ora J**, Rogliani P, Matera MG. Role of muscarinic antagonists in asthma therapy. *Expert Review of Respiratory Medicine* [Internet]. 2017;11(3):239–53. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85013820746&doi=10.1080%2f17476348.2017.1289844&partnerID=40&md5=01c84aad8408eda24f74d138abd224bf>
69. Cazzola M, **Ora J**, Puxeddu E, Rogliani P. Indacaterol/Glycopyrronium Combination for COPD. *Pulmonary Therapy* [Internet]. 2017;3(1):45–57. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85032734287&doi=10.1007%2fs41030-016-0024-0&partnerID=40&md5=21fc2b3daab3b0a861f2a545d2b7bc00>
70. Calzetta L, Rogliani P, **Ora J**, Puxeddu E, Cazzola M, Matera MG. LABA/LAMA combination in copd: A meta-analysis on the duration of treatment. *European Respiratory Review* [Internet]. 2017;26(143). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85010289798&doi=10.1183%2f16000617.0043-2016&partnerID=40&md5=ff5403697114f3d70f5a535355276348>
71. Calzetta L, **Ora J**, Cavalli F, Rogliani P, O'Donnell DE, Cazzola M. Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. *Respiratory Medicine* [Internet]. 2017;129:189–98. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85021646271&doi=10.1016%2fj.rmed.2017.06.020&partnerID=40&md5=cb32cf27d43fd39598e6b93377055626>
72. Braidò F, Baiardini I, Alleri P, Bacci E, Barbetta C, Bellocchia M, et al. Asthma management in a specialist setting: Results of an Italian Respiratory Society survey. *Pulmonary Pharmacology and Therapeutics* [Internet]. 2017;44:83–7. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85016325173&doi=10.1016%2fj.pupt.2017.03.013&partnerID=40&md5=7763458663fa5e9ead5908ale19ca17d>
73. Salvati A, **Ora J**, Donatucci B, Rogliani P. Cardiopulmonary exercise test in athletes and coronary diseases. *Medicina dello Sport* [Internet]. 2016;69(2):289–96. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84992476758&partnerID=40&md5=73c3fae7cff2d155050e9b9b5ab79770>
74. Rogliani P, Puxeddu E, Ciaprinì C, **Ora J**, Onorato A, Pezzuto G, et al. The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils. *BioMed Research International* [Internet]. 2016;2016. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0->

84994641724&doi=10.1155%2f2016%2f4547953&partnerID=40&md5=2e5ac7b9860c8d1ba00a1fb61ac1088e

75. Rogliani P, **Ora J**, Puxeddu E, Cazzola M. Airflow obstruction: Is it asthma or is it COPD? *International Journal of COPD* [Internet]. 2016;11(1):3007–13. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85007490506&doi=10.2147%2fCOPD.S54927&partnerID=40&md5=a50411e4e1976ad4fc45079d8c3eaac1>

76. Liccardi G, Salzillo A, Calzetta L, **Ora J**, Rogliani P. Gastroesophageal reflux and COPD exacerbations: Is cholinergic-mediated oesophago-bronchial reflex a possible link? *Respirology* [Internet]. 2016;21(8):1496–7. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84991490860&doi=10.1111%2fresp.12896&partnerID=40&md5=fc9eda530c719c5c07405513796d8110>

77. Liccardi G, Salzillo A, Calzetta L, **Ora J**, Rogliani P. Dog allergen immunotherapy and allergy to furry animals. *Annals of Allergy, Asthma and Immunology* [Internet]. 2016;116(6):590. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84971673298&doi=10.1016%2fj.anai.2016.04.007&partnerID=40&md5=35e1cd04f83163099b1e81ceb8946775>

78. Liccardi G, Salzillo A, Calzetta L, **Ora J**, Cazzola M, Matera MG, et al. Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma? *Journal of Allergy and Clinical Immunology: In Practice* [Internet]. 2016;4(4):791–3. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018669250&doi=10.1016%2fj.jaip.2016.03.025&partnerID=40&md5=e3558f67661a383e30002c514d671663>

79. Faisal A, Alghamdi BJ, Ciavaglia CE, Elbehairy AF, Webb KA, **Ora J**, et al. Common mechanisms of dyspnea in chronic interstitial and obstructive lung disorders. *American Journal of Respiratory and Critical Care Medicine* [Internet]. 2016;193(3):299–309. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84961190233&doi=10.1164%2fajrccm.201504-0841OC&partnerID=40&md5=cf9db730ee05c59af73e4a6b911df6a0>

80. Cazzola M, Rogliani P, **Ora J**, Matera MG. Treatment options for moderate-to-very severe chronic obstructive pulmonary disease. *Expert Opinion on Pharmacotherapy* [Internet]. 2016;17(7):977–88. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84961393014&doi=10.1517%2f14656566.2016.1155555&partnerID=40&md5=d71525ff72e92b0d61c1fe1f318607d9>

81. Cazzola M, Rinaldi B, Lucà G, **Ora J**. Olodaterol for the treatment of asthma. *Expert Opinion on Investigational Drugs* [Internet]. 2016;25(7):861–6. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84969850223&doi=10.1080%2f13543784.2016.1188078&partnerID=40&md5=117551238d1b794474bea7e959987857>

82. Cazzola M, **Ora J**, Puxeddu E. Dual bronchodilation and exacerbations of COPD. *Journal of Thoracic Disease* [Internet]. 2016;8(9):2383–6. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84991217836&doi=10.21037%2fjtd.2016.08.92&partnerID=40&md5=43bb6122006d40836d35558d0268140a>

83. Cazzola M, **Ora J**, Di Paolo A, Puxeddu E, Calzetta L, Rogliani P. Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD. *Pulmonary Pharmacology and Therapeutics* [Internet]. 2016;39:48–53. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84976359294&doi=10.1016%2fj.pupt.2016.06.006&partnerID=40&md5=976fdc5541f2a52870b2d4c0026227b9>

84. Cazzola M, Calzetta L, Puxeddu E, **Ora J**, Facciolo F, Rogliani P, et al. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. *Respiratory Research* [Internet]. 2016;17(1). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84973623311&doi=10.1186%2fs12931-016-0386-8&partnerID=40&md5=8019fba0502d3ea2f2e64e757d9f0030>
85. Rogliani P, Calzetta L, **Ora J**, Lipsi R, Segreti A, Matera MG, et al. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. *European Journal of Pharmacology* [Internet]. 2015;761:383–90. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84938950539&doi=10.1016%2fj.ejphar.2015.04.042&partnerID=40&md5=af6813713bd6ea417fd0cfc0b19f498>
86. Rogliani P, Calzetta L, **Ora J**, Matera MG. Canakinumab for the treatment of chronic obstructive pulmonary disease. *Pulmonary Pharmacology and Therapeutics* [Internet]. 2015;31:15–27. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84926285094&doi=10.1016%2fj.pupt.2015.01.005&partnerID=40&md5=38fe6d2bc73c4ebfffe960baafba5432>
87. Matera MG, **Ora J**, Cazzola M. Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – Focus on olodaterol. *Therapeutics and Clinical Risk Management* [Internet]. 2015;11:1805–11. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84949756566&doi=10.2147%2fTCRM.S73581&partnerID=40&md5=512f6d8510c5bb9fc1931d805229baa0>
88. Cazzola M, Segreti A, Capuano R, Bergamini A, Martinelli E, Calzetta L, et al. Analysis of exhaled breath fingerprints and volatile organic compounds in COPD. *COPD Research and Practice* [Internet]. 2015;1(1). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85002446906&doi=10.1186%2fs40749-015-0010-1&partnerID=40&md5=eb5b6eac0ae8ded38b74e72d2023659b>
89. Cazzola M, Rogliani P, **Ora J**, Matera MG. Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. *Expert Review of Clinical Pharmacology* [Internet]. 2015;8(5):529–39. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84939784979&doi=10.1586%2f17512433.2015.1075389&partnerID=40&md5=a9446c202efe68e88a0e6b6a58ee7019>
90. Cazzola M, Calzetta L, **Ora J**, Puxeddu E, Rogliani P, Matera MG. Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside. *Respiratory Medicine* [Internet]. 2015;109(10):1305–11. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84942885527&doi=10.1016%2fj.rmed.2015.08.005&partnerID=40&md5=d74aeada2b130ac5c24f5f0c67aa14bb>
91. Rogliani P, **Ora J**, Ciapriani C, Senis L, Stirpe E, Cazzola M. Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. *Respiratory Medicine* [Internet]. 2014;108(2):307–13. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84893724878&doi=10.1016%2fj.rmed.2013.10.022&partnerID=40&md5=84889a0acd15a0b2b25c0eaf8337477f>
92. Ciavaglia CE, Guenette JA, **Ora J**, Webb KA, Neder JA, O'Donnell DE. Does exercise test modality influence dyspnoea perception in obese patients with COPD? *European Respiratory Journal* [Internet]. 2014;43(6):1621–30. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0->

84901847720&doi=10.1183%2f09031936.00151513&partnerID=40&md5=76dff6c210a9eaaa4a36d3f072f98aea

93. **Ora J**, Calzetta L, Pezzuto G, Senis L, Paone G, Mari A, et al. A 6MWT index to predict O₂ flow correcting exercise induced SpO₂ desaturation in ILD. *Respiratory Medicine* [Internet]. 2013;107(12):2014–21. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84890312181&doi=10.1016%2fj.rmed.2013.10.002&partnerID=40&md5=4ed142f32d59c4133ea885f7a3961bfa>

94. Fiorentini A, **Ora J**, Tubani L. Autonomic system modification in zen practitioners. *Indian Journal of Medical Sciences* [Internet]. 2013;67(7–8):161–7. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84893872404&doi=10.4103%2f0019-5359.125877&partnerID=40&md5=08a7e21e7f802caee6f35ad17d99fb02>

95. Cazzola M, Segreti A, Stirpe E, Puxeddu E, **Ora J**, Rogliani P, et al. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. *Respiratory Medicine* [Internet]. 2013;107(1):107–11. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84871358712&doi=10.1016%2fj.rmed.2012.09.022&partnerID=40&md5=56e42b4e3eddcdd02b48586fc6c6659e>

96. Loughheed MD, **Ora J**, O'Donnell DE. Long-Acting Muscarinic Antagonists in Asthma and COPD. In: *Advances in Combination Therapy for Asthma and COPD* [Internet]. 2012. p. 268–95. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84886165950&doi=10.1002%2f9781119998624.ch11&partnerID=40&md5=8d4a4b31f6666d86a8c96d6cee3da3e5>

97. **Ora J**, Laveneziana P, Wadell K, Preston M, Webb KA, O'Donnell DE. Effect of obesity on respiratory mechanics during rest and exercise in COPD. *Journal of Applied Physiology* [Internet]. 2011;111(1):10–9. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-79960276266&doi=10.1152%2fjappphysiol.01131.2010&partnerID=40&md5=ea6dc17321dfaf2574a3bd85c49713a1>

98. Laveneziana P, Webb KA, **Ora J**, Wadell K, O'Donnell DE. Evolution of dyspnea during exercise in chronic obstructive pulmonary disease impact of critical volume constraints. *American Journal of Respiratory and Critical Care Medicine* [Internet]. 2011;184(12):1367–73. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84455201660&doi=10.1164%2frcm.201106-1128OC&partnerID=40&md5=3c80290ed7bdf7eedf11d9f8226493f>

99. Aliverti A, Kayser B, Mauro ALO, Quaranta M, Pompilio P, Dellacà RL, et al. Respiratory and leg muscles perceived exertion during exercise at altitude. *Respiratory Physiology and Neurobiology* [Internet]. 2011;177(2):162–8. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-79957517119&doi=10.1016%2fj.resp.2011.03.014&partnerID=40&md5=f55d88f80717156dd45bb3a2a6510102>

100. **Ora J**, O'Donnell DE. Modern management of chronic obstructive pulmonary disease. *Minerva Pneumologica* [Internet]. 2010;49(1):1–16. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-77953585631&partnerID=40&md5=1cfe09c3e68038a03538def55a1d8874>

101. **Ora J**, Jensen D, O'Donnell DE. Exertional dyspnea in chronic obstructive pulmonary disease: Mechanisms and treatment approaches. *Current Opinion in Pulmonary Medicine* [Internet]. 2010;16(2):144–9. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-76449091139&doi=10.1097%2fMCP.0b013e328334a728&partnerID=40&md5=5a7b4788da7f06105c485c18700ad554>

102. O'Donnell DE, **Ora J**, Laveneziana P. Clinical benefits of maximal bronchodilation in chronic obstructive pulmonary disease (Part I). Hot Topics in Respiratory Medicine [Internet]. 2010;(12):25–32. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-79957469879&partnerID=40&md5=4f75f46d9868d61f568af219dbd44712>
103. Deesomchok A, Fisher T, Webb KA, **Ora J**, Lam YM, Loughheed MD, et al. Effects of obesity on perceptual and mechanical responses to bronchoconstriction in asthma. American Journal of Respiratory and Critical Care Medicine [Internet]. 2010;181(2):125–33. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-74949131555&doi=10.1164%2frcm.200906-0934OC&partnerID=40&md5=9459724c21f80193cced174fe9fc2491>
104. **Ora J**, Laveneziana P, Ofir D, Deesomchok A, Webb KA, O'Donnell DE. Combined effects of obesity and chronic obstructive pulmonary disease on dyspnea and exercise tolerance. American Journal of Respiratory and Critical Care Medicine [Internet]. 2009;180(10):964–71. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-72849133815&doi=10.1164%2frcm.200904-0530OC&partnerID=40&md5=6159af71104d5bb968c59e4d5bc0dce8>
105. O'Donnell DE, **Ora J**, Webb KA, Laveneziana P, Jensen D. Mechanisms of activity-related dyspnea in pulmonary diseases. Respiratory Physiology and Neurobiology [Internet]. 2009;167(1):116–32. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-67349130812&doi=10.1016%2fj.resp.2009.01.010&partnerID=40&md5=b69cedcc2fe1932aa4cf c075fb6ecc3e>
106. O'Donnell DE, Laveneziana P, **Ora J**, Webb KA, Lam YM, Ofir D. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage i COPD. Thorax [Internet]. 2009;64(3):216–23. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-61649088166&doi=10.1136%2fthx.2008.103598&partnerID=40&md5=eb05ca278add2d72a323 5ef88a5c80c3>
107. Laveneziana P, Palange P, **Ora J**, Martolini D, O'Donnell DE. Bronchodilator effect on ventilatory, pulmonary gas exchange, and heart rate kinetics during high-intensity exercise in COPD. European Journal of Applied Physiology [Internet]. 2009;107(6):633–43. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-76649126384&doi=10.1007%2fs00421-009-1169-4&partnerID=40&md5=69cb6aa9e6dc2b5f0ed995a5112d1958>
108. Onorati P, Martolini D, **Ora J**, Valli G, Fedeli A, Palange P. Estimation of the exercise ventilatory compensation point by the analysis of the relationship between minute ventilation and heart rate. European Journal of Applied Physiology [Internet]. 2008;104(1):87–94. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-46749083342&doi=10.1007%2fs00421-008-0777-8&partnerID=40&md5=a7122fbb35ae91f435795df7914c5c2f>

Autorizzo il trattamento dei miei dati personali presenti nel CV ai sensi dell'art. 13 d. lgs. 30 giugno 2003 n. 196 - "Codice in materia di protezione dei dati personali" e dell'art. 13 GDPR 679/16 - "Regolamento europeo sulla protezione dei dati personali".

23 settembre 2025

Josuel Ora

